Variant: rs121913279 

    present in Gene: PIK3CA
    present in Chromosome: 3
    Position on Chromosome: 179234297
    Alleles of this Variant: A/G;T

rs121913279 in PIK3CA gene and Adenocarcinoma of lung (disorder) PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Adenocarcinoma of pancreas PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Adenocarcinoma of prostate PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Adrenocortical carcinoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Brain Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Brain Stem Glioma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and CLAPO Syndrome PMID 29446767 2018 CLAPO syndrome: identification of somatic activating PIK3CA mutations and delineation of the natural history and phenotype.

rs121913279 in PIK3CA gene and Colorectal Carcinoma PMID 15994075 2005 The prevalence of PIK3CA mutations in gastric and colon cancer.

PMID 15930273 2005 Functional analysis of PIK3CA gene mutations in human colorectal cancer.

rs121913279 in PIK3CA gene and Colorectal Neoplasms PMID 19366826 2009 PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.

PMID 19903786 2009 PIK3CA mutations predict local recurrences in rectal cancer patients.

PMID 20619739 2010 Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

PMID 15016963 2004 High frequency of mutations of the PIK3CA gene in human cancers.

PMID 20453058 2010 Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.

PMID 15254419 2004 The PIK3CA gene is mutated with high frequency in human breast cancers.

PMID 22162582 2012 Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 22162589 2012 Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

PMID 18725974 2008 Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

PMID 15647370 2005 Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

PMID 19223544 2009 PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

rs121913279 in PIK3CA gene and Congenital Lipomatous Overgrowth, Vascular Malformations, and Epidermal Nevi PMID 22658544 2012 Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome.

rs121913279 in PIK3CA gene and Congenital macrodactylia PMID 23100325 2013 Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly.

rs121913279 in PIK3CA gene and Cutaneous Melanoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Esophageal carcinoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Gastric Adenocarcinoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Glioblastoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Liver carcinoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Malignant Uterine Corpus Neoplasm PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Malignant neoplasm of breast PMID 16353168 2006 PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.

rs121913279 in PIK3CA gene and Malignant neoplasm of ovary PMID 15520168 2004 Mutation of the PIK3CA gene in ovarian and breast cancer.

rs121913279 in PIK3CA gene and Mammary Neoplasms PMID 15805248 2005 PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

PMID 15254419 2004 The PIK3CA gene is mutated with high frequency in human breast cancers.

PMID 15647370 2005 Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

PMID 22162582 2012 Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.

PMID 18676830 2008 An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

PMID 18725974 2008 Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 22162589 2012 Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

PMID 21558396 2011 The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.

PMID 20453058 2010 Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.

rs121913279 in PIK3CA gene and Medulloblastoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Neoplasms PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

rs121913279 in PIK3CA gene and Non-Small Cell Lung Carcinoma PMID 22162589 2012 Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

PMID 19029981 2008 Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

PMID 19513541 2009 A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.

PMID 18725974 2008 Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

PMID 16930767 2006 PIK3CA mutation status in Japanese lung cancer patients.

PMID 20453058 2010 Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.

PMID 15647370 2005 Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

PMID 16906227 2006 Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

PMID 21430269 2011 Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

PMID 15254419 2004 The PIK3CA gene is mutated with high frequency in human breast cancers.

PMID 15016963 2004 High frequency of mutations of the PIK3CA gene in human cancers.

rs121913279 in PIK3CA gene and Renal Cell Carcinoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Seborrheic keratosis PMID 17673550 2007 By contrast, 10 of 62 (16%) SK revealed the typical cancer-associated PIK3CA mutations E542K, E545K, and H1047R.

rs121913279 in PIK3CA gene and Serous cystadenocarcinoma ovary PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Squamous cell carcinoma of lung PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Squamous cell carcinoma of the head and neck PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Transitional cell carcinoma of bladder PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Uterine Carcinosarcoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and Uterine Cervical Neoplasm PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913279 in PIK3CA gene and ovarian neoplasm PMID 22271473 2012 PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.

PMID 15647370 2005 Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.